FloraWorks, a leading cannabinoid therapeutics company, conducted a groundbreaking double-blind, randomized, placebo-controlled trial on its flagship product, TruCBN™—”an ultra-pure cannabinol” and now, “the first CBN ingredient with clinically validated claims for treating sleep disturbances.”
The clinical trial was independently conducted by Radicle Science. The study involved over 1,000 participants in the U.S. who received different doses of TruCBN™, melatonin, or a placebo. One of the main findings from the trial pointed out that the group taking 50 mg of FloraWorks’ CBN ingredient “showed a significant improvement in sleep compared to placebo.” Additionally, the TruCBN™ group had “slightly better sleep improvements compared to [the individuals taking] 4 mg of melatonin.”
FloraWorks’ CEO and co-founder, Alleh Lindquist, emphasized that these findings open the door to more effective sleep solutions that will benefit millions.
Image Credit: FloraWorks
#SleepSupporting #CBN #Ingredients #CBN #ingredient
